BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 5, 2005
View Archived Issues
MediBIC and Threshold sign glufosfamide codevelopment agreement
Read More
Dacogen NDA accepted for filing
Read More
SuperGen withdraws Orathecin NDA
Read More
AtheroGenics proposes amendments to ARISE trial of AGI-1067
Read More
NIK-333 set to enter phase II
Read More
Kinase inhibitors disclosed in Janssen patent
Read More
CRF receptor antagonists for depression, anxiety, etc.
Read More
Novel, selective estrogen receptor beta agonists in early development at Lilly
Read More
Celltech team describes novel series of chemokine CXCR3 receptor modulators
Read More
Pfizer claims compounds with dual 5-HT4 agonist/5-HT3 antagonist activity for GI disorders
Read More
New checkpoint kinase 2 inhibitors identified at Janssen
Read More
Amgen patent covers new cytokine inhibitors
Read More
New eNOS expression enhancers under investigation at Aventis
Read More
Characterization of the mechanism of action of the tumor-targeting combi-molecule ZR-2002
Read More
Pharmacokinetics of R-411 determined in healthy subjects
Read More
Afelimomab reduces mortality due to severe sepsis
Read More
Garenoxacin exposure-response relationship studied with trial data
Read More
FDA approves new oral solution formulation of Abilify
Read More
Ampligen investigated in HIV-1 patients coinfected with HCV
Read More
New data on the efficacy and safety of lapatinib in breast cancer
Read More
Enrollment under way in phase I study of TD-2749 for GI motility dysfunction
Read More
Preclinical and clinical studies evaluate the effects of interferon alpha on CNS
Read More
Olanzapine reported to reduce the risk of violent behavior in schizophrenia
Read More
VGV-1 reduces plasma viral load in HIV-infected patients not responding to antiretroviral therapy
Read More
Merck & Co. develops MB-243, a novel melanocortin receptor agonist
Read More